BG Medicine announces data presentations on galectin-3 at Heart Failure Congress 2010

BG Medicine, Inc., a U.S. based, privately-held biomarker discovery and in vitro diagnostics company, announced today that there will be several data presentations regarding galectin-3 at the Heart Failure Congress 2010, the annual scientific meeting of the Heart Failure Association of the European Society of Cardiology, to be held in Berlin, Germany, on May 29^th through June 1^st. BG Medicine has developed and applied for FDA clearance of an in vitro diagnostic test to measure galectin-3 levels in plasma or serum.

Certain of the data presentations regarding galectin-3 include:

Sponsored Symposium: 'Galectin-3: a novel biomarker of fibrosis in heart failure'

Co-Chairs: Dirk Jan van Veldhuisen (Groningen, NL) and Michael Boehm (Homburg/Saar, DE)

I. Galectin-3 Biology: Remodeling and Progression of Heart Failure — Faiez Zannad (Nancy, FR); Program # 678.

II. Galectin-3 in Heart Failure: Clinical Evidence — Lars Gullestad (Oslo, NO); Program #679.

III. Role of Galectin-3 in the Management of Heart Failure — Dirk Jan van Veldhuisen (Groningen, NL); Program #680.

For further information about the symposium, go to: http://tinyurl.com/2u69fph

Poster Presentation:
Program #234: 'Does the severity of LV dysfunction or the extent of myocardial scar explain elevations in plasma galectin-3 in patients with heart failure?' by Nasser Sherwi, on behalf of John G.F. Cleland and colleagues (Hull, GB). For more information: http://tinyurl.com/358qsr7

Oral Presentation:
Program #612: 'Novel biomarkers of cardiovascular risk prediction and patient segmentation', by Peter Gardiner, Senior Medical Officer, BG Medicine. For more information: http://tinyurl.com/35ae72v